FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186089382> ?p ?o ?g. }

• W2186089382 endingPage "4444" @default.
• W2186089382 startingPage "4434" @default.
• W2186089382 abstract "BMS-914392 is a tricyclic pyranoquinoline BCS class 2 weak base that demonstrates high solubility in low pH environments. Initial clinical studies indicated that rapid release of high dose BMS-914392 led to transient adverse events associated with peak plasma concentrations. A modified release (MR) formulation strategy was proposed to suppress the peak blood concentration and maintain total exposure to overcome the adverse effects. Three modified release prototype formulations were developed and tested via a USP 3 dissolution method to verify that each formulation can effectively slow the release of BMS-914392. A pharmacokinetic (PK) absorption model was employed to guide the formulation development and selection. Simulations showed good agreement with plasma levels measured after oral dosing in dogs. Identification of key formulation factors to achieve release rates suitable for blunting peak blood levels without diminishing exposure were achieved through combined preclinical data and use of GastroPlus simulations. PK absorption model refinements based on phase 1 data, dog pharmacokinetic results, and in vitro data provided reliable predictions of human absorption profiles and variability in patients. All three prototype formulations demonstrated lower maximum plasma concentrations of BMS-914392 and maintained satisfactory relative bioavailability. Both the PK absorption model and subsequent clinical data indicated that an acidified hydrophilic matrix MR formulation had the greatest potential to reduce the incidence of adverse events and showed the best exposure profile in fasted state healthy subjects with and without famotidine coadministration. The risk based development process achieved successful screening and selection of a suitable modified release formulation to enable clinical efficacy trials." @default.
• W2186089382 created "2016-06-24" @default.
• W2186089382 creator A5001238517 @default.
• W2186089382 creator A5012215036 @default.
• W2186089382 creator A5017022833 @default.
• W2186089382 creator A5018929375 @default.
• W2186089382 creator A5024436649 @default.
• W2186089382 creator A5038330603 @default.
• W2186089382 creator A5039851737 @default.
• W2186089382 creator A5044159184 @default.
• W2186089382 creator A5045873955 @default.
• W2186089382 creator A5065447516 @default.
• W2186089382 creator A5086525654 @default.
• W2186089382 date "2015-11-04" @default.
• W2186089382 modified "2023-10-12" @default.
• W2186089382 title "Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis" @default.
• W2186089382 cites W104741800 @default.
• W2186089382 cites W1555656429 @default.
• W2186089382 cites W1841919898 @default.
• W2186089382 cites W1980754521 @default.
• W2186089382 cites W1983473009 @default.
• W2186089382 cites W2007416715 @default.
• W2186089382 cites W2010258053 @default.
• W2186089382 cites W2025122753 @default.
• W2186089382 cites W2052956476 @default.
• W2186089382 cites W2064757035 @default.
• W2186089382 cites W2065233728 @default.
• W2186089382 cites W2082875971 @default.
• W2186089382 cites W2085495677 @default.
• W2186089382 cites W2086130473 @default.
• W2186089382 cites W2101199741 @default.
• W2186089382 cites W2124168315 @default.
• W2186089382 cites W2124954720 @default.
• W2186089382 cites W2133592825 @default.
• W2186089382 cites W2152666064 @default.
• W2186089382 cites W2498818599 @default.
• W2186089382 doi "https://doi.org/10.1021/acs.molpharmaceut.5b00624" @default.
• W2186089382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26536519" @default.
• W2186089382 hasPublicationYear "2015" @default.
• W2186089382 type Work @default.
• W2186089382 sameAs 2186089382 @default.
• W2186089382 citedByCount "12" @default.
• W2186089382 countsByYear W21860893822016 @default.
• W2186089382 countsByYear W21860893822017 @default.
• W2186089382 countsByYear W21860893822020 @default.
• W2186089382 countsByYear W21860893822022 @default.
• W2186089382 countsByYear W21860893822023 @default.
• W2186089382 crossrefType "journal-article" @default.
• W2186089382 hasAuthorship W2186089382A5001238517 @default.
• W2186089382 hasAuthorship W2186089382A5012215036 @default.
• W2186089382 hasAuthorship W2186089382A5017022833 @default.
• W2186089382 hasAuthorship W2186089382A5018929375 @default.
• W2186089382 hasAuthorship W2186089382A5024436649 @default.
• W2186089382 hasAuthorship W2186089382A5038330603 @default.
• W2186089382 hasAuthorship W2186089382A5039851737 @default.
• W2186089382 hasAuthorship W2186089382A5044159184 @default.
• W2186089382 hasAuthorship W2186089382A5045873955 @default.
• W2186089382 hasAuthorship W2186089382A5065447516 @default.
• W2186089382 hasAuthorship W2186089382A5086525654 @default.
• W2186089382 hasConcept C111113717 @default.
• W2186089382 hasConcept C112705442 @default.
• W2186089382 hasConcept C125287762 @default.
• W2186089382 hasConcept C150903083 @default.
• W2186089382 hasConcept C159985019 @default.
• W2186089382 hasConcept C181389837 @default.
• W2186089382 hasConcept C185592680 @default.
• W2186089382 hasConcept C192562407 @default.
• W2186089382 hasConcept C197934379 @default.
• W2186089382 hasConcept C207001950 @default.
• W2186089382 hasConcept C2777288759 @default.
• W2186089382 hasConcept C2780035454 @default.
• W2186089382 hasConcept C2781263782 @default.
• W2186089382 hasConcept C71924100 @default.
• W2186089382 hasConcept C86803240 @default.
• W2186089382 hasConcept C98274493 @default.
• W2186089382 hasConceptScore W2186089382C111113717 @default.
• W2186089382 hasConceptScore W2186089382C112705442 @default.
• W2186089382 hasConceptScore W2186089382C125287762 @default.
• W2186089382 hasConceptScore W2186089382C150903083 @default.
• W2186089382 hasConceptScore W2186089382C159985019 @default.
• W2186089382 hasConceptScore W2186089382C181389837 @default.
• W2186089382 hasConceptScore W2186089382C185592680 @default.
• W2186089382 hasConceptScore W2186089382C192562407 @default.
• W2186089382 hasConceptScore W2186089382C197934379 @default.
• W2186089382 hasConceptScore W2186089382C207001950 @default.
• W2186089382 hasConceptScore W2186089382C2777288759 @default.
• W2186089382 hasConceptScore W2186089382C2780035454 @default.
• W2186089382 hasConceptScore W2186089382C2781263782 @default.
• W2186089382 hasConceptScore W2186089382C71924100 @default.
• W2186089382 hasConceptScore W2186089382C86803240 @default.
• W2186089382 hasConceptScore W2186089382C98274493 @default.
• W2186089382 hasFunder F4320307115 @default.
• W2186089382 hasIssue "12" @default.
• W2186089382 hasLocation W21860893821 @default.
• W2186089382 hasLocation W21860893822 @default.
• W2186089382 hasOpenAccess W2186089382 @default.
• W2186089382 hasPrimaryLocation W21860893821 @default.
• W2186089382 hasRelatedWork W16113689 @default.

• next